It seems increasingly important to define prognostic subgroups in CLL, both in early and advanced stages. The analysis of interphase cytogenetics appears particularly promising in this regard. By the use of modern techniques including FISH, chromosomal aberrations can be found in about four out of five patients [1] . The 13q-deletion is detected in 53% of patients and therefore the most frequent chromosomal aberration in CLL (H. Dohner, Heidelberg, Germany). Patients with a single 13q-aberration show a trend for a better survival (> 15 years). The trisomy 12 represents the second most frequent abnormality (16%) and has a worse prognosis than the 13q-karyotype. Besides age and Rai stage, the chromosomal aberrations of llq-and 17p-are the most relevant prognostic factors predicting a median survival of less than six years. Sequential interphase cytogenetic reveal that in about one out of four patients a clonal evolution occurs during disease progression.
Risk assessment is not only based on cytogenetic parameters, but also on markers of tumor mass or some adhesion molecules. High-risk patients show elevated levels of serum(s) CD23, spVmicroglobulin, sCD25 and sCD27 (S. Molica, Catanzaro, Italy) [2] . Furthermore, adhesion molecules like sCD54 and sVEGF, as well as the intracellular expression of bcl-2 are of prognostic relevance. Future studies with large numbers of patients will have to determine which of these parameters will have definitive, independent prognostic value.
New insights into the pathogenesis
With regard to the pathophysiology, CLL can be understood as the result of an increased input of signals which prevent programmed cell death (F. Schriever, Berlin, Germany; Table 1 ). For example, the bcl-2 protein is overexpressed in CLL; its expression seems to correlate with a decreased survival. [3] . In contrast to the imbalance of apoptotic signals, alterations in the expression of genes which regulate the cell cycle, seems an uncommon event. For example, the inactivation of Rb or cyclin dependent kinase 1, as well as the amplification of cyclin gene expression are observed rarely in CLL. F. Ajchenbaum-Cymbalista (Paris, France) hypothesized that the protein products of cell cycle regulatory genes might be altered by post-translational modifications, thereby altering the function of the CLL cell. The CLL cell seems committed to the early Gi rather than Go phase of cell cycle, since the expression of Gi cyclins like cyclin D2 and E as well as cyclin dependent kinase 4 is higher than in resting cells. Moreover, cyclin kinase inhibitors might play a crucial role: p27 is highly expressed; this phenomenon is correlated with a shorter lymphocyte doubling time and a poor prognosis [4] . p23, a truncated form of p27 lacking the C-terminus (containing the caspase function), seems to be specifically overexpressed in CLL cells. Future experiments will show whether inhibition of this isoform is a therapeutic option.
Autoimmune phenomena
Another unresolved issue in CLL is the pathomechanism of autoimmune disease. F. Caligaris-Cappio (Torino, Italy) explained that autoimmunity in CLL can be explained as the result of the production of polyclonal, self-antigen restricted auto-antibodies against hematopoietic cells [5] . One important antigen seems to be the B-cell receptor (BCR) which is altered in CLL. Here expression of CD79b which represents the extracellular epitope of the BCR, is lacking in about 75% of patients, resulting from alternative splicing of exon 3 of the BCR gene. How can the malignant CD5+ cell characterized by insufficient surface expression of the BCR, low expression of costimulatory molecules like CD80 and CD86, function as antigen presenting cell for T-and B-cell induction? One hypothesis is that antigens are presented by B-CLL cells especially in the spleen (where many hematopoietic cells are homing), thus inducing normal B cells to produce polyclonal autoantibodies against hematopoietic cells. Whatever the pathogenesis, the treatment of autoimmune disorders of the hematopoietic system (thrombocytopenia, anemia) in CLL is relatively well defined (L. F. Diehl, Washington, DC, USA) [6] . Standard treatment is prednisone (1 mg/kg/d). In cases with a hemoglobin of less than 6 g/dl, intravenous immunoglobins are recommended. Cyclosporin is reserved for severe cases, resulting frequently in clinical improvements. Splenectomy has only a minor role in the therapy of autoimmune disease. It should be emphasized that maintenance therapy is needed in most cases. Fludarabine can induce autoimmune hemolytic anemia (AIHA). However, AIHA is a disorder occuring independent of fludarabine. Therefore, fludarabine treatment is not strictly contraindicated in CLL after the development of AIHA, but these patients should be monitored more carefully under fludarabine treatment.
New therapeutic perspectives
What are the perspectives of a modern treatment of CLL? It should no longer be the general principle to perform a palliative therapy for all patients with CLL, but rather a risk-adapted therapy for the individual patient. K. Rai (New York) suggested that a young patient with active disease should be vigorously treated to induce a complete remission. Induction therapy should include fludarabine; attempts should be made to eradicate minimal risidual disease using monoclonal antibodies (Campath, a-CD20) or other immunotherapies. For refractory cases allo-transplantation should be considered. For the young patient with indolent disease and good prognostic markers, a defensive strategy ('wait and watch') can be justified. The old patient with active disease should be initially treated with the goal to induce a CR; thereafter, a quality-of-life analysis should guide the decision whether to wait or to treat further.
Fludarabine combinations
One important and meanwhile widely accepted agent in the treatment of CLL is the purine analog fludarabine. But only about half of the patients respond completely to fludarabine and the response is not sustained in all patients. A way to improve the outcome is the use of fludarabine in combination with other chemotherapeutic agents. E. Montserrat (Barcelona) presented data from a trial with a combination consisting of fludarabine (25 mg, di_ 3 ), mitoxantrone (8 mg, d]), and cyclophosphamide (600 mg, di) (FMC) conducted in 27 patients, most of them in Binet stage B and C. The overall response (OR) rate in these pretreated patients was 81% with 7% molecular remissions, 41% CR and 33% PR. The median time to treatment failure was 10 months, the median survival time 25 months and the median follow-up time 12 months. Besides hematological toxicity, severe infections up to grade 4 were observed in about 10%, the treatment related toxicity was about 5%. These complications seem to be the price for the much better response rate when compared with fludarabine monotherapy (OR 28%, CR 4%).
New drugs
What are the new drugs arising on the horizon of CLL therapy? B. Cheson (Bethesda) presented several promising drugs which might find access to broader application in the future. One of these is 'compound 506', a prodrug of ara-G and inhibitor of DNA synthesis [7] . It has shown activity in heavily pretreated T-ALLs and NHL [8] . In phase I trials, CNS toxicity was described including seizures and ataxia which was dose-limiting. A phase I trial in CLL patients was carried out by S. O'Brien at the M.D. Anderson Cancer Center in Houston, where this drug was combined with fludarabine. Besides peripheral neuropathy, only mild myelosuppression was observed. Another interesting drug is Flavopiridol (NSC 649890), a semi-synthetic flavone derivate which targets kinases and inhibits CDK and protein kinase C [9] . The substance decreases bcl-2 and induces apoptosis independent of the p53 status of the cell. In a phase I trial only secretory diarrhea and no myelotoxicity was observed [10] . This drug is now investigated in large clinical trials.
A substance which started more empirically and belongs now to the arsenal of CLL therapeutics is CAMPATH-1H, a humanized anti-CD52 antibody. CD52 is expressed on more than 95% of human lymphocytes and is the target of complement-mediated lysis by the antibody. A. Osterborg (Stockholm) presented data of a phase II multicenter study which showed a 42% OR rate in previously treated CLL patients who received the CAM PATH-1H antibody three times a week over 12 weeks [11] . Interestingly, the antibody was very potent in reducing lymphadenopathy. Side effects included grade 4 thrombo-and neutropenia as well as long-lasting lymphocytopenia, especially of CD4+/ CD8+ lymphocytes. A present study uses the antibody in previously untreated patients with B-CLL by subcutaneous application. A preliminary analysis showed CRs including regression of lymphadenopathy in 10 out of 11 patients, while side effects were mainly local skin reactions and a transient grade 4 neutropenia.
A gene therapeutic approach was presented by T. Kipps (San Diego). CLL cells transduced by an adenoviral vector expressing the CD40L molecule enhanced the expression of costimulatory molecules as well as adhesion molecules on the infected tumor cells [12] . When CD40L-transduced CLL cells were injected into the patient, a systemic immune response against the leukemic cells was induced. CTLs taken from the vaccination site were cytotoxic not only for the transduced CLL cells, but also for non-modified autologous leukemic B cells. Meanwhile a clinical phase I protocol was closed at the University of California at San Diego (UCSD): the first patients who received their own CD40L-transduced CLL cells tolerated the treatment well without apparent side effects, a significant increase in the number of anti-CLL CTLs and a transient decrease of peripheral blood CLL cells could be documented.
High-dose chemotherapy
High-dose chemotherapy with transplantation of hematopoietic progenitor cells is another alternative to control the disease. E. Monserrat (Barcelona) summarized the results of an international project comparing patients (most of them stage Binet B) receiving either allo-or autotransplantation of hematopoietic progenitor cells. The CR rate after autologous transplantation was higher (81%) than with allogeneic cells (61%). Importantly the treatment related mortality was significantly lower for patients receiving autologous stem cells (8% vs. 39%). The number of long-term survivors was higher after allogeneic transplantation, reflecting the lower relapse rates in this group (40% vs. 15%). Both procedures are feasible, but opportunistic infections have to be taken into account (including toxoplasmosis and listeriosis). In conclusion, the role of transplantation is not yet established in randomized trials which are urgently needed in the future.
The German CLL Study Group has initiated a large trial to test the feasibility and efficacy of autologous PBSCT in CLL (CLL3 protocol). This protocol includes patients up to 60 years. After cytoreductive pretreatment with CHOP or fludarabine, stem-cell mobilization with DexaBEAM is performed. Patients are treated with TBI and cyclophosphamide before stem cells are reinfused. P. Dreger (Kiel) presented first data of 28 patients who were eligible for this study. Critical for a good mobilization of stem cells is the time from diagnosis to start of chemotherapy which was at an average 11 months. So far, no mobilization failure occured. The possibility to induce molecular remissions was predicted by the presence of bone marrow infiltration and the time interval from diagnosis to treatment. Therefore, P. Dreger concludes that transplantation should be performed as early as possible.
I. Khouri (Houston, TX, USA) presented the M.D. Anderson 'mini transplant concept' [13] . Patients received an immunosuppressive, non-myeloablative chemotherapy with fludarabine (30 mg/m 2 ) and cyclophosphamide (300 mg/m 2 ) over three days. Thereafter, allogeneic peripheral blood stem cells are reinfused, and later donor lymphocytes if needed. Fifteen patients with a median age of 55 years and with an average of three prior chemotherapies had a 100% response rate (CR 73%, PR 27%) and a survival of 50% at one year after treatment. The toxicity was low with one death after liver failure and two cases of extensive graft-ver^MJ-host disease (GvHD). In future trials the role of immunosuppressive drugs will be studied for prophylaxis of GvHD. Taken together the concept of mini-transplants seems feasible for refractory patients who are heavily pretreated and out of range for allogeneic transplantation due to their age.
M. Michallet (Lyon, France) summarized the experience of the European Bone Marrow Transplant (EBMT) registry for transplantation of CLL patients. So far, 377 patients were transplanted, 184 received an allogeneic and 193 an autologous transplant. The median age of allo-transplant patients was 43 years, for autologous recipients 50 years. Most of the autologous stem cells were purged (80%), 74% by negative selection. The source of allogeneic stem cells was in > 80% of cases a sibling donor. 46% of patients undergoing allogeneic transplantation developed GvHD. The mortality rate of allogeneic versus autologous transplant patients was 52 versus 16%. Only 48% of all allo transplant patients are still alive while 84% of the autologous transplant patients live. Therefore the EBMT data seem to favor the strategy of an early autologous transplantation in CLL.
Occurence and prevention of infectious complications
Bacterial infections with staphylococcus aureus, streptococci and H. influenzae are the most common infections in CLL, while fungal and viral infections only play a minor role (V. A. Morrison; Minneapolis, MN, USA) [14] . Mucosal immunity is disrupted in CLL and patients with low IgA serum levels and alkylator therapy show the most serious infections. Furthermore, in CLL the salivary IgM is significantly lower than in the control population. Under therapy, most infectious complications develop during the first three months of treatment.
Patients under fludarabine show more major infections. In particular, the rate of HSV infections is significantly increased.
Whether prophylactic strategies can reduce infectious complications in CLL patients is presently unknown. T. Siidhoff (Diisseldorf, Germany) recommended a pneumocystis prophylaxis in patients with concurrent steroids and CD4 counts below 500/ul [15] . Listeriosis as seen in about 3% of patients under fludarabine and steroids should be prevented by dietary measures. In a prospective trial the role of antiviral drugs and G-CSF will be established based on first experiences from O'Brien and colleagues at the MD Anderson Cancer Center who showed a decrease of pneumonias in G-CSF treated patients in comparison to historical controls. The CLL6 protocol of the GCLLSG will test the benefit of G-CSF after FMC chemotherapy in a phase III trial.
An interesting observation of an infectious etiology or complication of CLL was discussed by B. Rotoli (Naples, Italy). The Italian group observed an increased prevalence of hepatitis C virus (HCV) infections in lymphoproliferative disorders including CLL (28%); in contrast, almost no HCV infections were found in these diseases in the UK [16] . HCV positive CLL patients show significant differences for gender, splenomegaly, Rai stage and IgM levels. It is unclear whether these patients have a different HLA susceptibility for HCV infections. In a current Italian study it will be tested whether HCV positive patients benefit from treatment with interferon-oc.
Conclusion
The rapidly growing understanding of cytogenetic and molecular events in CLL will elucidate the pathomechanism and help to better define the risk of a rapid disease progression. From these developments, a risk adapted, individually tailored therapy will be developed in the near future. Purine analogs in combination with other cytotoxic drugs should provide therapies with tolerable toxicity but increased efficacy, at least in terms of their potential to induce complete remissions. Transplantation of autologous or allogeneic stem cells will allow to administer even higher doses and induce more complete remissions. It will then depend on the success of new, adjuvant treatment concepts, in particular on immunotherapies with gene-modified CLL cells or monoclonal antibodies, whether it will be possible to maintain these complete remissions in order to translate them into cure for patients with CLL.
